ReviewFrontiers in immunology2021
Interaction Networks Converging on Immunosuppressive Roles of Granzyme B: Special Niches Within the Tumor Microenvironment.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Optimized patient-derived lung cancer organoids recapitulating the immune landscape for precision therapy evaluation.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Possible Applications of Azurin, a Copper-Containing Protein, in Cancer Treatment: Prospects and Challenges.Current drug targets · 2026Review
- BCL-2 Inhibitor Regulates Number, Function, and Antitumor Immunity of T Cells by Influencing Glycolysis in AML.Cancer science · 2025Article
- Effect of Curcuma Longa Extract to Granzyme Expression and Tumor Mass Diameter of Mammary Adenocarcinoma with Chemotherapy Adriamycin Cyclophosphamide: An Animal Study in Rats.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Efficient colorimetric assay promotes the virtual screen of granzyme B inhibitors.Mikrochimica acta · 2025Article
- Single-cell spatial proteomics of non-relapse small cell lung cancer identifies tumor microenvironment determinants of survival.Cell biology and toxicology · 2025Article
- Targeting inflammation in cancer therapy: from mechanistic insights to emerging therapeutic approaches.Journal of translational medicine · 2025Review
- Sonodynamic Therapy Induces Pyroptosis and Recruits CAR-NK Cells to Enhance the Treatment of Oral Squamous Cell Carcinoma.ACS applied materials & interfaces · 2025Article
- Comprehensive Analysis of Granzymes and Perforin Family Genes in Multiple Cancers.Biomedicines · 2025Article
- The pro-tumorigenic roles of granzyme B: mechanisms and therapeutic implications.Frontiers in immunology · 2025Review
- Multiplex imaging of localized prostate tumors reveals altered spatial organization of AR-positive cells in the microenvironment.iScience · 2024Article
- Granzymes in health and diseases: the good, the bad and the ugly.Frontiers in immunology · 2024Review
- Effect of tumor-associated macrophages on the pyroptosis of breast cancer tumor cells.Cell communication and signaling : CCS · 2023Review
- Imaging of Activated T Cells.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Review
- A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells.Frontiers in immunology · 2023Article
- The Association of CD8+ Cytotoxic T Cells and Granzyme B+ Lymphocytes with Immunosuppressive Factors, Tumor Stage and Prognosis in Cutaneous Melanoma.Biomedicines · 2022Article
- A truncated derivative of FGFR1 kinase cooperates with FLT3 and KIT to transform hematopoietic stem cells in syndromic and de novo AML.Molecular cancer · 2022Article
- Nanobiotherapeutic strategies to target immune microenvironment of triple-negative breast cancer.American journal of cancer research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Granzyme B is a renowned effector molecule primarily utilized by CTLs and NK cells against ill-defined and/or transformed cells during immunosurveillance. The overall expression of granzyme B within tumor microenvironment has been well-established as a prognostic marker indicative of priming immunity for a long time. Until recent years, increasing immunosuppressive effects of granzyme B are unveiled in the setting of different immunological context. The accumulative evidence confounded the roles of granzyme B in immune responses, thereby arousing great interests in characterizing detailed feature of granzyme B-positive niche. In this paper, the granzyme B-related regulatory effects of major suppressor cells as well as the tumor microenvironment that defines such functionalities were longitudinally summarized and discussed. Multiplex networks were built upon the interactions among different transcriptional factors, cytokines, and chemokines that regarded to the initiation and regulation of granzyme B-mediated immunosuppression. The conclusions and prospect may facilitate better interpretations of the clinical significance of granzyme B, guiding the rational development of therapeutic regimen and diagnostic probes for anti-tumor purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.